中医药治疗心血管疾病:证据与潜在机制
该综述系统评估了中医药在心血管疾病中的疗效与安全性及活性成分的药理机制。现有随机对照试验存在样本量小、结局指标异质等缺陷,难以得出确切结论;结果表明中医药可能作为心血管疾病一级和二级预防的补充替代方法,但仍需严格设计的随机对照试验评估长期硬终点。
要点
- 现有中医药随机对照试验样本量小、结局多样,难以确定实际获益与风险
- 中医药可能作为心血管疾病一级和二级预防的补充替代方法
- 需严格设计的随机对照试验评估中医药对长期硬终点的效果
核心结论
- 中医药可能作为心血管疾病一级和二级预防的补充替代方法
- 需进一步严格设计的随机对照试验评估长期硬终点效果
研究设计与样本
- 系统评估中医药对心血管疾病的疗效与安全性及活性成分药理机制
- 现有随机对照试验存在样本量小、结局指标异质等缺陷
主要发现
- 因现有随机对照试验缺陷,难以得出中医药实际获益与危害的确定结论
临床怎么用
- 中医药可考虑作为心血管疾病一级和二级预防的补充替代方法
- 需注意现有证据级别有限,长期硬终点获益尚不明确
局限性
- 现有随机对照试验样本量小且结局指标多样
- 缺乏评估长期硬终点的严格设计随机对照试验
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Traditional Chinese medicine (TCM) has more than 2,000 years of history and has gained widespread clinical applications. However, the explicit role of TCM in preventing and treating cardiovascular disease remains unclear due to a lack of sound scientific evidence. Currently available randomized controlled trials on TCM are flawed, with small sample sizes and diverse outcomes, making it difficult to draw definite conclusions about the actual benefits and harms of TCM. Here, we systematically assessed the efficacy and safety of TCM for cardiovascular disease, as well as the pharmacological effects of active TCM ingredients on the cardiovascular system and potential mechanisms. Results indicate that TCM might be used as a complementary and alternative approach to the primary and secondary prevention of cardiovascular disease. However, further rigorously designed randomized controlled trials are warranted to assess the effect of TCM on long-term hard endpoints in patients with cardiovascular disease.
引用
- Hao P, Jiang F, Cheng J, et al. Traditional Chinese Medicine for Cardiovascular Disease: Evidence and Potential Mechanisms. J Am Coll Cardiol. 2017. PMID: 28619197. doi:10.1016/j.jacc.2017.04.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。